GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » VGI Health Technology Ltd (XNEC:VTL) » Definitions » Gross-Profit-to-Asset %

VGI Health Technology (XNEC:VTL) Gross-Profit-to-Asset % : 0.00% (As of . 20)


View and export this data going back to 2021. Start your Free Trial

What is VGI Health Technology Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. VGI Health Technology's annualized Gross Profit for the quarter that ended in . 20 was A$ Mil. VGI Health Technology's average Total Assets over the quarter that ended in . 20 was A$ 0 Mil. Therefore, VGI Health Technology's annualized Gross-Profit-to-Asset % for the quarter that ended in . 20 was Not Available.

VGI Health Technology Gross-Profit-to-Asset % Historical Data

The historical data trend for VGI Health Technology's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

VGI Health Technology Gross-Profit-to-Asset % Chart

VGI Health Technology Annual Data
Trend
Gross-Profit-to-Asset %

VGI Health Technology Semi-Annual Data
Gross-Profit-to-Asset %

Competitive Comparison of VGI Health Technology's Gross-Profit-to-Asset %

For the Biotechnology subindustry, VGI Health Technology's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

VGI Health Technology's Gross-Profit-to-Asset % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, VGI Health Technology's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where VGI Health Technology's Gross-Profit-to-Asset % falls into.


VGI Health Technology Gross-Profit-to-Asset % Calculation

VGI Health Technology's annualized Gross-Profit-to-Asset % for the fiscal year that ended in . 20 is calculated as:

Gross-Profit-to-Asset %=Gross Profit (A: . 20 )/( (Total Assets (A: . 20 )+Total Assets (A: . 20 ))/ count )
=/( (+)/ )
=/
= %

VGI Health Technology's annualized Gross-Profit-to-Asset % for the quarter that ended in . 20 is calculated as:

Gross-Profit-to-Asset %=Gross Profit (Q: . 20 )/( (Total Assets (Q: . 20 )+Total Assets (Q: . 20 ))/ count )
=/( (+)/ )
=/
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is one times the annual (. 20) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.

VGI Health Technology Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of VGI Health Technology's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.

VGI Health Technology Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » VGI Health Technology Ltd (XNEC:VTL) » Definitions » Gross-Profit-to-Asset %
Comparable Companies
Traded in Other Exchanges
N/A
Address
19 Martin Place, Level 45, Suite 03, Sydney, NSW, AUS, 2003
Website
https://www.vgiht.com
VGI Health Technology Ltd develops and commercializes evidence-based nutraceuticals and pharmaceuticals. It has two evidence-based nutraceutical products ready for commercial launch in the US as well as a therapeutic drug development program. The nE1-Heart targets maintenance of heart health - tocotrienols have a similar mode of action (inhibition of HMCG CoA biosynthesis) as statins, the Gold Standard for treatment of hyperlipidaemia; and nE1-Eliteth that reduces Delayed Onset Muscle Soreness, improves muscle recovery after exercise, exercise endurance and maintenance of peak muscle power.

VGI Health Technology Headlines

No Headlines